Insmed (INSM) Competitors $98.18 +1.52 (+1.57%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$98.18 0.00 (0.00%) As of 07/11/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INSM vs. TAK, ARGX, BNTX, ONC, TEVA, SMMT, ITCI, GMAB, RDY, and MRNAShould you be buying Insmed stock or one of its competitors? The main competitors of Insmed include Takeda Pharmaceutical (TAK), argenex (ARGX), BioNTech (BNTX), BeOne Medicines (ONC), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry. Insmed vs. Its Competitors Takeda Pharmaceutical argenex BioNTech BeOne Medicines Teva Pharmaceutical Industries Summit Therapeutics Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Moderna Takeda Pharmaceutical (NYSE:TAK) and Insmed (NASDAQ:INSM) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment. Which has more volatility and risk, TAK or INSM? Takeda Pharmaceutical has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500. Comparatively, Insmed has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Do institutionals & insiders have more ownership in TAK or INSM? 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by insiders. Comparatively, 3.0% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts rate TAK or INSM? Insmed has a consensus target price of $108.07, indicating a potential upside of 10.07%. Given Insmed's higher possible upside, analysts plainly believe Insmed is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Insmed 0 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to TAK or INSM? In the previous week, Insmed had 6 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 11 mentions for Insmed and 5 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 1.55 beat Insmed's score of 0.95 indicating that Takeda Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Insmed 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is TAK or INSM more profitable? Takeda Pharmaceutical has a net margin of 2.36% compared to Insmed's net margin of -265.93%. Takeda Pharmaceutical's return on equity of 10.64% beat Insmed's return on equity.Company Net Margins Return on Equity Return on Assets Takeda Pharmaceutical2.36% 10.64% 5.14% Insmed -265.93%-446.98%-52.70% Which has higher earnings & valuation, TAK or INSM? Takeda Pharmaceutical has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTakeda Pharmaceutical$30.09B1.55$712.33M$0.2266.68Insmed$363.71M51.21-$913.77M-$5.95-16.50 SummaryTakeda Pharmaceutical beats Insmed on 9 of the 15 factors compared between the two stocks. Get Insmed News Delivered to You Automatically Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INSM vs. The Competition Export to ExcelMetricInsmedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.34B$2.99B$5.60B$9.11BDividend YieldN/A2.39%5.24%4.02%P/E Ratio-16.5020.5827.9620.25Price / Sales51.21291.28430.5799.61Price / CashN/A42.8637.4658.16Price / Book61.367.638.045.49Net Income-$913.77M-$55.05M$3.18B$250.27M7 Day Performance-0.32%8.39%3.63%4.75%1 Month Performance1.34%5.35%4.04%7.64%1 Year Performance27.99%1.95%29.56%16.34% Insmed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INSMInsmed4.3567 of 5 stars$98.18+1.6%$108.07+10.1%+27.5%$18.34B$363.71M-16.501,271Analyst ForecastInsider TradeTAKTakeda Pharmaceutical2.1134 of 5 stars$15.07-1.8%N/A+9.6%$47.95B$30.09B68.5047,455Positive NewsARGXargenex4.3989 of 5 stars$546.04+0.5%$728.06+33.3%+21.3%$33.34B$2.25B33.691,599Analyst UpgradeBNTXBioNTech1.4923 of 5 stars$110.05+0.0%$137.86+25.3%+33.3%$26.45B$2.98B-32.376,772News CoverageAnalyst ForecastONCBeOne Medicines3.446 of 5 stars$240.99-1.8%$320.67+33.1%N/A$26.41B$4.18B-64.7811,000Trending NewsAnalyst DowngradeInsider TradeTEVATeva Pharmaceutical Industries4.1355 of 5 stars$16.84-1.0%$24.13+43.3%-4.2%$19.31B$16.54B-14.6436,830SMMTSummit Therapeutics2.8189 of 5 stars$22.61-7.9%$34.67+53.3%+188.0%$16.79B$700K-66.50110ITCIIntra-Cellular Therapies0.6601 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S4.1087 of 5 stars$20.52+1.1%$37.60+83.2%-18.4%$13.16B$3.12B11.662,682Analyst ForecastRDYDr. Reddy's Laboratories2.7589 of 5 stars$15.08flat$16.95+12.4%-7.9%$12.59B$3.81B22.8527,811MRNAModerna4.3068 of 5 stars$29.90-1.9%$46.61+55.9%-72.6%$11.56B$3.24B-3.425,800Trending News Related Companies and Tools Related Companies Takeda Pharmaceutical Competitors argenex Competitors BioNTech Competitors BeOne Medicines Competitors Teva Pharmaceutical Industries Competitors Summit Therapeutics Competitors Intra-Cellular Therapies Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Moderna Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INSM) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Insmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
